Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Patient-blinded randomized controlled trial evaluating length and quality of prostate biopsies taken by a novel biopsy needle.
Prostate biopsy is the golden standard for prostate cancer diagnosis. Transrectal prostate biopsy (TRUSbx) is the most widely used technique. The biopsy chamber of the Tru Cut needle is in general 19 mm. However, it is on average filled only with 13 mm of tissue. Biopsy length is strongly correlated with diagnostic accuracy of prostate cancer.
Additionally, TRUSbx has a high risk of infection due to bacteria being brought across the colon wall. The investigators have shown that a new needle design reduces this bacterial transfer in an ex vivo setting and a previous trial (NCT049091230) has shown non inferior biopsy length when compared to the standard Tru Cut needle. A further improvement of the needle has now been designed aiming to increase biopsy length and quality, with the possible potential to improve prostate cancer diagnosis. This is the first human pilot aiming to evaluate if biopsy length of the novel needle is superior to a standard Tru Cut biopsy needle in prostate biopsy.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Novel needle | Experimental | Novel needle (18 G, 25 cm with 19 mm sample notch) in a new actuator. |
|
| Standard Tru Cut needle | Active Comparator | Standard tru cut biopsy needle (Argon 18G, 25 cm biopsy needle with a 19 mm sample notch) in a standard actuator (Möller Medical Blue RBG-1000-10-1000). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Novel needle (18 G, 25 cm with 19 mm sample notch) in a new actuator. | Device | Trans Rectal Ultrasound guided Prostate Biopsy using the assigned needle. Approximately 12 biopsies per patient. |
| Measure | Description | Time Frame |
|---|---|---|
| Prostate biopsy length (measured by pathologist) | Length of biopsy specimen in millimeters | within 21 days post biopsy |
| Measure | Description | Time Frame |
|---|---|---|
| Prostate biopsy fragmentation | The number of sections the biopsy specimen is made of | within 21 days post biopsy |
| General appearance of biopsy assessed by pathologist (biopsy quality) | General quality of biopsy specimen on a scale from 0-3 (no biopsy, poor, good, excellent) |
| Measure | Description | Time Frame |
|---|---|---|
| Pain from biopsy sampling | Numeric rating Pain Scale rating from 0-10 | At the time of biopsy sampling |
| 14 day complications | Any complications related to the biopsy (example infection, bleeding) |
Inclusion Criteria:
Exclusion Criteria:
- None (other than general contraindications for prostate biopsy or patient not willing to participate)
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Andreas Forsvall | Contact | 0046-42-4063121 | andreas.forsvall@med.lu.se | |
| Adam Linder, Ass prof | Contact | 0046-46-171000 | adam.linder@med.lu.se |
| Name | Affiliation | Role |
|---|---|---|
| Adam Linder, Ass prof | Lund University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Helsingborg Hospital | Recruiting | Helsingborg | Skåne County | 254 37 | Sweden |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33999764 | Result | Forsvall A, Fisher J, Wagenius M, Broman C, Korkocic D, Bratt O, Linder A. Prostate biopsy quality and patient experience with the novel Forsvall biopsy needle - a randomized controlled non-inferiority trial. Scand J Urol. 2021 Jun;55(3):235-241. doi: 10.1080/21681805.2021.1921024. Epub 2021 May 17. | |
| 33999753 | Result |
| Label | URL |
|---|---|
| Forsvall et al. Prostate biopsy quality and patient experience with the novel Forsvall biopsy needle - a randomized controlled non-inferiority trial. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
60 patients eligible for prostate biopsy are randomized into 2 arms (30+30 patients) using either the novel needle and actuator device or standard Tru Cut needle and actuator device used in the clinic today. On average 12 biopsies are taken from each patient. Biopsy length (primary outcome) is evaluated by a pathologist who is blinded to device used.
Not provided
Not provided
Patient and pathologist are unaware of which needle/device is used. All biopsies are taken from behind the back of the patient enabling masking from the patient. To assess masking success, patients will be asked to guess which device was used after the procedure is complete.
|
| Standard Tru Cut biopsy needle (Argon 18G, 25 cm biopsy needle with a 19 mm sample notch) in a standard actuator (Möller Medical Blue RBG-1000-10-1000) | Device | Trans Rectal Ultrasound guided Prostate Biopsy using the assigned needle. Approximately 12 biopsies per patient. |
|
|
| within 21 days post biopsy |
| Prostate biopsy length (measured in biopsy needle chamber) | Length of biopsy specimen in millimeters | within 21 days post biopsy |
| Prostate biopsy length (measured after removal from biopsy chamber) | Length of biopsy specimen in millimeters | within 21 days post biopsy |
| 14 days after biopsy |
| 30 day complications | Any complications related to the biopsy (example infection, bleeding) | 30 days after biopsy |
| Forsvall A, Fisher J, Cardoso JFP, Wagenius M, Tverring J, Nilson B, Dahlin A, Bratt O, Linder A, Mohanty T. Evaluation of the Forsvall biopsy needle in an ex vivo model of transrectal prostate biopsy - a novel needle design with the objective to reduce the risk of post-biopsy infection. Scand J Urol. 2021 Jun;55(3):227-234. doi: 10.1080/21681805.2021.1921023. Epub 2021 May 17. |
| Forsvall et al, Evaluation of the Forsvall biopsy needle in an ex vivo model of transrectal prostate biopsy | View source |
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| D004194 | Disease |
| D009369 | Neoplasms |
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D011469 | Prostatic Diseases |
| ID | Term |
|---|---|
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
Not provided
Not provided
| ID | Term |
|---|---|
| D001707 | Biopsy, Needle |
| ID | Term |
|---|---|
| D001706 | Biopsy |
| D003581 | Cytodiagnosis |
| D003584 | Cytological Techniques |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
| D013048 | Specimen Handling |
| D003949 | Diagnostic Techniques, Surgical |
| D013514 | Surgical Procedures, Operative |
| D011677 | Punctures |
| D008919 | Investigative Techniques |
Not provided
Not provided